Biomea Fusion Inc (BMEA)
12.22
-0.56
(-4.38%)
USD |
NASDAQ |
May 17, 16:00
12.22
0.00 (0.00%)
After-Hours: 20:00
Biomea Fusion Cash from Financing (TTM): 163.71M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 163.71M |
| December 31, 2023 | 163.80M |
| September 30, 2023 | 163.67M |
| June 30, 2023 | 163.93M |
| March 31, 2023 | 1.409M |
| December 31, 2022 | 1.239M |
| September 30, 2022 | 0.995M |
| Date | Value |
|---|---|
| June 30, 2022 | 0.595M |
| March 31, 2022 | 153.22M |
| December 31, 2021 | 153.18M |
| September 30, 2021 | 209.33M |
| June 30, 2021 | 209.33M |
| March 31, 2021 | 65.91M |
| December 31, 2020 | 65.97M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.595M
Minimum
Jun 2022
209.33M
Maximum
Jun 2021
108.31M
Average
153.20M
Median
Cash from Financing (TTM) Benchmarks
| Poseida Therapeutics Inc | 14.90M |
| Cartesian Therapeutics Inc | 29.74M |
| BioXcel Therapeutics Inc | 29.00M |
| NovaBay Pharmaceuticals Inc | 1.313M |
| Palatin Technologies Inc | 14.71M |